Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL
Status:
Active, not recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety profile of copanlisib at the
recommended dose (primary endpoint). The recommended dose of copanlisib for Japanese patients
will be determined in the dose escalation/safety evaluation part.